Table 2. Univariate analysis of... | American Society of Hematology

Table 2.

Univariate analysis of hematologic and molecular remission duration

Characteristic	PETHEMA			GIMEMA			PETHEMA plus GIMEMA
Characteristic	No. patients/ relapses^*	Remission duration at 3 y (%)^†	P	No. patients/ relapses^*	Remission duration at 3 y (%)^†	P	No. patients/ relapses^*	Remission duration at 3 y (%)^†	P
Total series	109/11/4	89/85		108/9/3	91/89		217/20/7	90/86	ns
Age
≤ 15	4/0/0	100		11/0/0	100		15/0/0	100
16-40	46/5/1	88/86		43/4/1	90/88		89/9/2	89/87
41-60	44/5/2	87/82	ns	48/5/2	89/85	ns	92/10/4	87/83	ns
61-70	11/1/1	91/82		5/0/0	100		16/1/1	94/87
> 70	4/0/0	100		1/0/0	100		5/0/0	100
Gender
Male	61/6/2	89/84	ns	50/6/2	87/83	ns	111/12/4	87/83	ns
Female	48/5/2	89/85		58/3/1	95/93		106/8/3	92/89
WBC (× 10⁹/L)
≤ 3.5	71/6/1	91/88		68/2/1	97/95		139/8/2	93/92
3.5-10	13/0/1	100/92	.01	16/1/0	94	< .0001	29/1/1	96/93	< .0001
10-50	19/3/2	82/73		13/3/1	75/68		32/6/3	77/69
> 50	6/2/0	67		11/3/1	72/64		17/5/1	69/64
Hemoglobin (g/dL)
≤ 10	69/6/2	91/88	ns	84/8/2	90/88	ns	153/14/4	90/87	ns
> 10	40/5/2	85/78		24/1/1	96/92		64/6/3	89/84
Platelets (× 10⁹/L)
≤ 10	19/1/1	94/86		15/3/0	78		34/4/1	85/81
11-40	64/9/3	84/79	.08	58/6/1	89/87	.01	122/15/4	86/83	.05
> 40	26/1/0	96		35/0/2	94		61/1/2	95
FAB subtype
Typical	90/7/3	91/87	.04	93/8/2	91/89	ns	183/15/5	91/88	.05
Variant	19/4/1	78/73		15/1/1	93/87		34/5/2	85/79
PML/RARα
BCR1/BCR2	61/5/3	91/85	ns	60/4/0	93	ns	121/9/3	91/89	ns
BCR3	46/6/1	85/83		41/4/3	90/83		87/10/4	87/82

Characteristic	PETHEMA			GIMEMA			PETHEMA plus GIMEMA
Characteristic	No. patients/ relapses^*	Remission duration at 3 y (%)^†	P	No. patients/ relapses^*	Remission duration at 3 y (%)^†	P	No. patients/ relapses^*	Remission duration at 3 y (%)^†	P
Total series	109/11/4	89/85		108/9/3	91/89		217/20/7	90/86	ns
Age
≤ 15	4/0/0	100		11/0/0	100		15/0/0	100
16-40	46/5/1	88/86		43/4/1	90/88		89/9/2	89/87
41-60	44/5/2	87/82	ns	48/5/2	89/85	ns	92/10/4	87/83	ns
61-70	11/1/1	91/82		5/0/0	100		16/1/1	94/87
> 70	4/0/0	100		1/0/0	100		5/0/0	100
Gender
Male	61/6/2	89/84	ns	50/6/2	87/83	ns	111/12/4	87/83	ns
Female	48/5/2	89/85		58/3/1	95/93		106/8/3	92/89
WBC (× 10⁹/L)
≤ 3.5	71/6/1	91/88		68/2/1	97/95		139/8/2	93/92
3.5-10	13/0/1	100/92	.01	16/1/0	94	< .0001	29/1/1	96/93	< .0001
10-50	19/3/2	82/73		13/3/1	75/68		32/6/3	77/69
> 50	6/2/0	67		11/3/1	72/64		17/5/1	69/64
Hemoglobin (g/dL)
≤ 10	69/6/2	91/88	ns	84/8/2	90/88	ns	153/14/4	90/87	ns
> 10	40/5/2	85/78		24/1/1	96/92		64/6/3	89/84
Platelets (× 10⁹/L)
≤ 10	19/1/1	94/86		15/3/0	78		34/4/1	85/81
11-40	64/9/3	84/79	.08	58/6/1	89/87	.01	122/15/4	86/83	.05
> 40	26/1/0	96		35/0/2	94		61/1/2	95
FAB subtype
Typical	90/7/3	91/87	.04	93/8/2	91/89	ns	183/15/5	91/88	.05
Variant	19/4/1	78/73		15/1/1	93/87		34/5/2	85/79
PML/RARα
BCR1/BCR2	61/5/3	91/85	ns	60/4/0	93	ns	121/9/3	91/89	ns
BCR3	46/6/1	85/83		41/4/3	90/83		87/10/4	87/82

ns, not significant.

Number of patients/hematologic relapses/molecular relapses.

Uncensored event is hematologic relapse/hematologic and molecular relapses.